Sarah Hancox (@sarahhhancox) 's Twitter Profile
Sarah Hancox

@sarahhhancox

Doctor | Imperial graduate | Gastroenterology trainee in Yorkshire | Travel, scuba, netball

ID: 532228170

calendar_today21-03-2012 11:20:51

381 Tweet

130 Followers

243 Following

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 203 3/6 ⬜⬜⬜🟨🟩 🟩⬜⬜⬜🟩 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 205 5/6 ⬜⬜⬜⬜⬜ ⬜⬜🟨⬜🟨 ⬜🟩⬜🟨⬜ ⬜🟩⬜⬜🟨 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 206 3/6 ⬜🟩⬜⬜⬜ ⬜🟩⬜🟩🟩 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 207 5/6 ⬜🟨⬜⬜⬜ 🟨🟨⬜⬜⬜ ⬜🟨🟨⬜⬜ 🟩⬜🟨🟩⬜ 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 211 3/6 🟨🟩⬜⬜⬜ ⬜🟩⬜⬜🟩 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 212 4/6 ⬜⬜⬜⬜⬜ 🟨🟨⬜🟨🟨 🟨🟨⬜⬜🟨 🟩🟩🟩🟩🟩

Sarah Hancox (@sarahhhancox) 's Twitter Profile Photo

Wordle 214 6/6 🟨⬜🟩⬜⬜ ⬜⬜🟩🟨⬜ ⬜⬜🟩🟩🟩 ⬜⬜🟩🟩🟩 ⬜🟩🟩🟩🟩 🟩🟩🟩🟩🟩

Frontline Gastro (@frontgastro_bmj) 's Twitter Profile Photo

πŸ’‰ As use of subcutaneous infliximab in IBD gathers pace, what do we know about the immune response of patients treated with SC vs IV IFX? Sarah Hancox, Francesco Morda, Chris Black and Christian Selinger show that the risk of antidrug antibody formation is similar in SC vs IV

Jonny Blackwell (@jonnyblackwell) 's Twitter Profile Photo

This is really important! Previous studies showed v low rates of ADA when switching from IV to SC IFX. It was selection bias - those pts were already established on IFX & declared themselves as not being ADA formers. Sarah Hancox shows we still need IMM for new SC IFX.